|
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
|
3 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
|
Mar. 31, 2012
|
Mar. 31, 2011
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Revenue: | ||||
| PCT products, services, other | $ 164,772 | $ 180,643 | $ 767,765 | $ 877,567 |
| Grant revenue | 140,889 | 0 | 219,964 | 462,465 |
| Total revenue | 305,661 | 180,643 | 987,729 | 1,340,032 |
| Costs and expenses: | ||||
| Cost of PCT products and services | 78,194 | 78,929 | 342,865 | 376,514 |
| Research and development | 271,611 | 218,965 | 969,473 | 1,232,566 |
| Selling and marketing | 238,092 | 303,839 | 931,073 | 1,204,892 |
| General and administrative | 682,346 | 412,529 | 2,034,458 | 1,924,814 |
| Total operating costs and expenses | 1,270,243 | 1,014,262 | 4,277,869 | 4,738,786 |
| Operating loss | (964,582) | (833,619) | (3,290,140) | (3,398,754) |
| Other income (expense): | ||||
| Interest (expense) income | (56,313) | 254 | (136,595) | 2,303 |
| Therapeutic discovery credit | 0 | 244,479 | ||
| Change in fair value of warrant derivative liability | (42,012) | 0 | 430,423 | 0 |
| Total other income (expense) | (98,325) | 254 | 293,828 | 246,782 |
| Loss before income taxes | (2,996,312) | (3,151,972) | ||
| Income tax benefit | 0 | 23,710 | ||
| Net loss | (1,062,907) | (833,365) | (2,996,312) | (3,128,262) |
| Accrued interest on convertible debt | 18,896 | 0 | ||
| Accrued and deemed dividends on convertible preferred stock | (24,414) | (133,090) | (2,130,245) | (502,564) |
| Net loss applicable to common shareholders | $ (1,087,321) | $ (966,455) | $ (5,107,661) | $ (3,630,826) |
| Net loss per share attributable to common stockholders - basic and diluted (in dollars per share) | $ (0.14) | $ (0.34) | $ (0.77) | $ (1.35) |
| Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation (in shares) | 7,712,539 | 2,836,971 | 6,618,484 | 2,687,141 |
| X | ||||||||||
|
- Definition
Cost of developing and selling PCT products and providing related services. No definition available.
|
| X | ||||||||||
|
- Definition
Revenue generated from selling PCT products and providing related services. No definition available.
|
| X | ||||||||||
|
- Definition
The amount of expenses incurred for therapeutic discovery credit for the reporting entity. No definition available.
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS. No definition available.
|
| X | ||||||||||
|
- Definition
Net Increase or Decrease in the fair value of the derivative or group of derivatives included in earnings. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The after-tax amount of interest recognized in the period associated with any convertible debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|